Acceleron Pharma (XLRN) PT Raised to $139 at Goldman Sachs
Tweet
Share
E-mailGet Alerts XLRN Hot Sheet
Price: $178.75 --0%
Rating Summary:
11 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 19
Rating Summary:
11 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 19
Join SI Premium – FREE
Goldman Sachs analyst Corinne Jenkins raised the price target on Acceleron Pharma (NASDAQ: XLRN) to $139.00 (from $133.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gemini Space Station (GEMI) PT Lowered to $6 at Needham
- Deutsche Bank Downgrades Workday (WDAY) to Hold
- KinderCare Learning Companies (KLC) PT Lowered to $5 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
